ACS Medicinal Chemistry Letters · 2021 · 20 citations · 20 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationPharmacophore ModelingEnzyme InhibitionHit-to-lead OptimizationLigand BindingPharmacophore-based Lead DiscoveryPotency OptimizationStructure-activity Relationship AnalysisCell-based AssaysCell-based Potency AssaysCell-based Screening AssaysHistone DeacetylasesPharmacophore Model ConstructionPharmacophore Model OptimizationPharmacophore Model RefinementSelectivity
A novel series of histone deacetylase (HDAC) inhibitors lacking a zinc-binding moiety has been developed and described herein. HDAC isozyme profiling and kinetic studies indicate that these inhibitors display a selectivity preference for HDACs 1, 2, 3, 10, and 11 via a rapid equilibrium mechanism, and crystal structures with HDAC2 confirm that these inhibitors do not interact with the catalytic zinc. The compounds are nonmutagenic and devoid of electrophilic and mutagenic structural elements and exhibit off-target profiles that are promising for further optimization. The efficacy of this new class in biochemical and cell-based assays is comparable to the marketed HDAC inhibitors belinostat and vorinostat. These results demonstrate that the long-standing pharmacophore model of HDAC inhibitors requiring a metal binding motif should be revised and offers a distinct class of HDAC inhibitors.
20
Structure of HDAC3 bound to co-repressor and inositol tetraphosphate
Peter J. Watson, Louise Fairall, Guilherme Santos et al. · Nature · 2012 · 503 citations · Full text
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Christopher J. Millard, Peter J. Watson, Ivana Celardo et al. · Molecular Cell · 2013 · 397 citations · Full text
Richard D. Pearson, Young Kyeung Kim, Joseph Hokello et al. · Journal of Virology · 2008 · 307 citations · Full text